secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001708599-25-000110
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b
--------------------------------------------------------------------------------

- Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
- 10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.
- Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.
- Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.
- Maturity 5 years from initial funding; customary events of default with 2% default interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/ser-20250909.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer